港股异动 | 石四药集团(02005)再跌超4% 两款原料药获批上市此前预计全年纯利最多跌六成

智通财经03-02

智通财经APP获悉，石四药集团(02005)再跌超4%，截至发稿，跌3.7%，报2.6港元，成交额4024.5万港元。消息面上，石四药集团公告，本集团的甲氧氯普胺及盐酸甲氧氯普胺已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。两款原料药属于多巴胺受体D2拮抗剂，同时还具有5-羟色胺4（5-HT4）受体激动效应，促进胃肠动力，主要用于止吐及治疗恶心、嗳气、胃部胀满、返流性食管炎等疾病。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616884753?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-02 14:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616884753","market":"sh","top_or_hot":-1,"title":"港股异动 | 石四药集团(02005)再跌超4% 两款原料药获批上市 此前预计全年纯利最多跌六成","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，石四药集团(02005)再跌超4%，截至发稿，跌3.7%，报2.6港元，成交额4024.5万港元。消息面上，石四药集团公告，本集团的甲氧氯普胺及盐酸甲氧氯普胺已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。两款原料药属于多巴胺受体D2拮抗剂，同时还具有5-羟色胺4（5-HT4）受体激动效应，促进胃肠动力，主要用于止吐及治疗恶心、嗳气、胃部胀满、返流性食管炎等疾病。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408912.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 石四药集团(02005)再跌超4% 两款原料药获批上市 此前预计全年纯利最多跌六成</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 石四药集团(02005)再跌超4% 两款原料药获批上市 此前预计全年纯利最多跌六成\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 14:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1408912.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，石四药集团(02005)再跌超4%，截至发稿，跌3.7%，报2.6港元，成交额4024.5万港元。消息面上，石四药集团公告，本集团的甲氧氯普胺及盐酸甲氧氯普胺已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。两款原料药属于多巴胺受体D2拮抗剂，同时还具有5-羟色胺4（5-HT4）受体激动效应，促进胃肠动力，主要用于止吐及治疗恶心、嗳气、胃部胀满、返流性食管炎等疾病。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1408912.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2460026573.USD","symbol_name":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1408912.html","article_id":"2616884753","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616884753","pubTimestamp":1772434417,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，石四药集团再跌超4%，截至发稿，跌3.7%，报2.6港元，成交额4024.5万港元。消息面上，石四药集团公告，本集团的甲氧氯普胺及盐酸甲氧氯普胺已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。值得注意的是，石四药集团预计2025年度溢利将较上年度的10.61亿港元下降45%至60%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK1191":"制药","VT":"世界全股市ETF-Vanguard","02005":"石四药集团"},"translate_title":"Changes in Hong Kong stocks | Shisi Pharmaceutical Group (02005) fell more than 4% again. Two APIs were approved for listing. It was previously expected that full-year net profit would fall by up to 60%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VT":1.5,"VXUS":1.5,"02005":1.5},"content_text":"智通财经APP获悉，石四药集团(02005)再跌超4%，截至发稿，跌3.7%，报2.6港元，成交额4024.5万港元。消息面上，石四药集团公告，本集团的甲氧氯普胺及盐酸甲氧氯普胺已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。两款原料药属于多巴胺受体D2拮抗剂，同时还具有5-羟色胺4（5-HT4）受体激动效应，促进胃肠动力，主要用于止吐及治疗恶心、嗳气、胃部胀满、返流性食管炎等疾病。值得注意的是，石四药集团预计2025年度溢利将较上年度的10.61亿港元下降45%至60%。主要由于25年国内没有大规模流行病发生叠加医保控费导致药品终端销量下降、带量采购范围扩大以及国内外行业竞争加剧带来持续的价格压力以及盐酸溴己新安瓿注射液不再通过国家药品集采销售，导致营业额下降。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616884753","isCrawlerRequest":true}

港股异动 | 石四药集团(02005)再跌超4% 两款原料药获批上市 此前预计全年纯利最多跌六成

精彩评论

港股异动 | 石四药集团(02005)再跌超4% 两款原料药获批上市此前预计全年纯利最多跌六成